Trial Profile
Central Nervous System Effects of Liraglutide® 3.0 mg on Reward Mechanisms in Obese Patients Without Diabetes, in Relation to Food Addiction. A Randomized, Single-centre, Double-blind, Placebo Controlled Clinical Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms LIRAOB
- 29 Apr 2021 Status changed from active, no longer recruiting to completed.
- 14 Apr 2020 Planned End Date changed from 1 May 2020 to 30 Sep 2021.
- 06 Nov 2019 Status changed from recruiting to active, no longer recruiting.